CAL
JBIO

Capital Advisors Ltd’s Jade Biosciences JBIO Stock Holding History

Capital Advisors Ltd’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
6
– – ﹤0.01% 1365
2026
Q1 		$0 Hold
6
– – ﹤0.01% 1362
2025
Q4 		$0 Hold
6
– – ﹤0.01% 1347
2025
Q3 		$0 Hold
6
– – ﹤0.01% 1351
2025
Q2 		$0 Buy
+6
New +$204 ﹤0.01% 1339
2025
Q1 		– Hold
0
– – – 1332
2024
Q4 		– Hold
0
– – – 1365
2024
Q3 		– Hold
0
– – – 1362

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Advisors Ltd's JBIO Position: Q2 2026 in Review

Capital Advisors Ltd held its Jade Biosciences (JBIO) position steady in Q2 2026 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1365.

Capital Advisors Ltd first reported a position in JBIO in Q2 2025 and has held it in 5 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Capital Advisors Ltd held 6 shares of Jade Biosciences worth $0 as of Q2 2026.
  • Capital Advisors Ltd left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1365 holding.
  • Capital Advisors Ltd first reported a position in Jade Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.